icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Pharmstandard posts FY 2009 net profit of 6.85 billion roubles

Pharmstandard posts FY 2009 net profit of 6.85 billion roubles
Russian pharmaceutical drug producer, Pharmstandard, has posted a FY 2009 net profit of 6.852 billion roubles under IFRS.

The bottom line was up 96% year on year with FY 2009 EBITDA rising 59% to 9.41 billion roubles, as revenues climbed 68% to 24.095 billion roubles.

The company said the results were boosted by strong Arbidol sales, with a spike in purchasing stemming from widespread concerns about swine and bird influenza, and the drug widely believed to be effective against these. More broadly, Pharmstandard noted a 77% increase in pharmaceutical product sales, with a 36% decline in sales of medical equipment and disposables.

In an accompanying statement Pharmstandard also indicated that 1Q 2010 sales were up 25% to 5.727 billion roubles. 

Podcasts